Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 7/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.34 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824166 | 0.72 | LPL (0.44) | LPLLIPGP2RX7FFAR1MAPK1 | |
| SCHEMBL15148556 | 0.70 | CYP2A6 (0.50) | LPLLIPGCYP2A6 | |
| SCHEMBL20951809 | 0.69 | HMBS (0.40) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL18015249 | 0.69 | NPY5R (0.48) | — | |
| SCHEMBL1284338 | 0.67 | LPL (0.42) | LPLLIPGFFAR1 | |
| SCHEMBL16754612 | 0.67 | GSK3A (0.36) | LPLLIPGP2RX7FFAR1MAPK1 | |
| SCHEMBL1529678 | 0.65 | FFAR1 (0.36) | LPLLIPGP2RX7FFAR1 | |
| SCHEMBL858173 | 0.65 | ALDH1A1 (0.38) | HRH1HRH4LPLLIPGTSHR | |
| SCHEMBL31354826 | 0.65 | SMN1; SMN2 (0.50) | LPLLIPGFFAR1 | |
| SCHEMBL18125390 | 0.65 | GSK3A (0.38) | LPLLIPGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540127-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20230038512-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230038512-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11358948-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358948-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200377469-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377469-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-12-03 | — | — | US | disclosed |
| EP-3684366-A1 | CRBN LIGANDS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019060693-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019060693-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377469-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | HRH1 3306/4885HRH4 3010/4885LPL 4521/4885 |
| US-11358948-B2 | CRBN ligands and uses thereof | CRBN, CRKL, ERBB3 | HRH1 3306/4885HRH4 3010/4885LPL 4521/4885 |
| US-20230038512-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | HRH1 3306/4885HRH4 3010/4885LPL 4521/4885 |
| US-12540127-B2 | CRBN ligands and uses thereof | CRBN, NR2C2, NR2E3 | HRH1 1969/4885HRH4 946/4885LPL 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.